行情

IRWD

IRWD

Ironwood医药
NASDAQ

实时行情|Nasdaq Last Sale

11.11
+0.09
+0.82%
盘后: 11.11 0 0.00% 16:06 11/11 EST
开盘
11.01
昨收
11.02
最高
11.14
最低
10.81
成交量
90.18万
成交额
--
52周最高
13.00
52周最低
7.59
市值
17.42亿
市盈率(TTM)
-369.1030
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IRWD 新闻

  • FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
  • Zacks.16小时前
  • Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue?
  • Zacks.3天前
  • Pharma Sector Tops in October: Best ETFs & Stocks
  • Zacks.3天前
  • Edited Transcript of IRWD earnings conference call or presentation 31-Oct-19 12:30pm GMT
  • Thomson Reuters StreetEvents.5天前

更多

所属板块

生物技术和医学研究
-0.40%
制药与医学研究
-0.41%

热门股票

名称
价格
涨跌幅

IRWD 简况

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
展开

Webull提供Ironwood Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。